

## Data Sheet

### **Spike S1, Fc Fusion, Avi-tag** **(SARS-CoV-2)**

SARS-CoV-2, Recombinant, C-terminal  
 Fc-Avi-tag  
**Catalog #:** 100719  
**Lot #:** 200422                      **Conc:** 0.90 mg/ml

**Formulated in:** 8 mM Phosphate, pH 7.4,  
 110 mM NaCl, 2.2 mM KCl, and 20%  
 glycerol.

**Stability:** At least 6 months at -80°C. *Avoid  
 freeze/thaw cycles.*

**References:**

1. Hoffman, M. *et al.*, *Cell*. 2020 Apr;  
**181**:1-10.
2. Walls, A. C. *et al.*, *Cell*. 2002 Mar;  
**180**:1-12


**Description:** Severe acute respiratory  
 Coronavirus 2 Spike Glycoprotein S1 (SARS-  
 CoV-2 Spike S1), GenBank Accession No.  
 QHD43416.1, a.a. 16-685, fused at the C-  
 terminus of the Fc portion of human IgG1, with  
 a C-terminal Avi-tag™, expressed in a  
 HEK293 expression system, MW=104 kDa.  
 This protein runs at a higher MW by SDS-  
 PAGE due to glycosylation.

**Assay Conditions:** SARS-CoV-2 S1 (BPS  
 Bioscience #100719) and ACE2 binding  
 assay was done using BPS ACE2:SARS-  
 CoV-2 Spike Inhibitor Screening Assay Kit  
 (BPS Bioscience #79936). SARS-CoV-2 S1  
 (BPS Bioscience #100719) protein and anti-  
 human Fc-HRP were used instead of SARS-  
 CoV-2 Spike protein (RBD) and anti-mouse  
 Fc-HRP respectively.

**Applications:** Useful for the study of enzyme  
 kinetics, screening inhibitors, and selectivity  
 profiling.

### **Quality Assurance**

**ACE2:SARS-CoV-2 Inhibition**




**4-20% SDS-PAGE**  
**Coomassie staining**

**Lane 1:**  
 4µg SARS-CoV-2 S1  
**Lane 2:**  
 Protein Marker

**MW:** 104 kDa

**Purity:** ≥90%



OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**  
 Or you can Email us at: [info@bpsbioscience.com](mailto:info@bpsbioscience.com)  
 Please visit our website at: [www.bpsbioscience.com](http://www.bpsbioscience.com)